Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTRACTIVE 1: ATR-258 in Healthy and T2DM Participants
NCT05409924Phase 1Completed
- Sponsor
- Atrogi
- Start
- Apr 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ATR-258 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Atrogi. Primary endpoints: Safety analyses after single dose of ATR-258 and Safety analyses after multiple doses of ATR-258. Started Apr 2022; status: completed.
02
Drugs
ATR-258
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05409924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05409924.